Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsBlue Cross Blue Shield NM Drug List Coverage Updat…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentBlue Cross Blue Shield - New MexicoPolicy N/A

    Blue Cross and Blue Shield of New Mexico Drug List (Formulary) — Coverage Criteria

    Customize your policy alerts

    Sign up for all Blue Cross Blue Shield - New Mexico policy alerts

    Know when Blue Cross Blue Shield - New Mexico releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Governs which prescription and specialty drugs BCBSNM will cover for members, describes member responsibilities, prior authorization, quantity limits, step therapy, specialty pharmacy rules, and exclusions. Affects BCBSNM members and their prescribing providers and pharmacies.

    Policy Summary
    PayerBlue Cross Blue Shield - New Mexico
    PolicyDrug List (Formulary) — Coverage Criteria
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateJanuary 2026
    Next Review DateN/A
    Key ActionObtain prior authorization for products marked 'PA' and use participating specialty suppliers for drugs marked 'SP'.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    ME90ME limit token
    7Initial opioid IR supply (days)
    30Specialty max supply (days)
    14-15d x2Split fill regimen
    1-866-689-1523Member Services

    Coverage Criteria and Formulary Controls

    Standard coverage conditions

    Covered when ALL of the following are met

    Member and dispensing requirements: Member has a medical need for the medication and the prescription is filled at an in-network pharmacy; specialty drugs must be dispensed by a participating specialty supplier (Accredo preferred) or an approved limited distribution pharmacy.

    Sources: [[chunk 1]], [[chunk 14]]

    Authorization and program compliance: Drugs labeled 'PA' require prior authorization before coverage; drugs labeled 'QL' are subject to quantity limits; drugs labeled 'ST' are subject to step therapy; specialty drugs (SP) require prior authorization and must be obtained from an in-network specialty supplier.

    Sources: [[chunk 10]], [[chunk 14]]

    Specialty split-fill and initial dispensing: For new specialty drug starts labeled 'SF', the Specialty Pharmacy Split Fill Program applies: initial dispensing is a 14- or 15-day supply twice a month for the first two to three months to establish dosing and limit waste; thereafter standard monthly supplies may be provided.
    Policy Summary
    PayerBlue Cross Blue Shield - New Mexico
    PolicyDrug List (Formulary) — Coverage Criteria
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateJanuary 2026
    Next Review DateN/A
    Key ActionObtain prior authorization for products marked 'PA' and use participating specialty suppliers for drugs marked 'SP'.
    SourceLink
    On This Page
    Coverage Criteria and Formulary ControlsFormulary Product Listings, Flags, and Key ValuesPrior Authorization, Step Therapy, Documentation, and Denial RisksInitial Therapy and Specialty Split-FillStep Therapy Controls and NotationQuantity Limits and Day-Supply ExamplesSpecialty Distribution and Administration SitesBiosimilar Notes and ExamplesBackground and ScopeDefinitions and Formulary AbbreviationsKey Contacts and How to Request AuthorizationPolicy Revision History

    Source: [[chunk 12]]

    General formulary coverage

    Coverage is conditioned on plan-tier rules and utilization controls as annotated per drug entry (PA, QL, SP, SF, 90-day mail).

    Formulary coverage rules: Drug coverage follows the formulary tier assignment and any utilization controls listed on the product entry; coverage requires compliance with listed actions (e.g., PA, QL, ST, SF, SP, 90-day mail), and exceptions must be requested per plan procedures.

    Sources: [[chunk 126]], [[chunk 144]]

    Formulary coverage with utilization controls

    Formulary coverage with utilization controls; coverage depends on tier and any indicated utilization control.

    General formulary rule: A listed drug is assigned a Tier Level (1 = generic, 2 = brand) and is subject to any listed utilization controls shown in the 'Necessary actions, restrictions, or limits on use' column (for example: PA, QL, SP, AL, SF). Coverage is contingent on meeting those controls or obtaining an approved exception.

    Examples: REPATHA (PA, QL), ORENITRAM (PA, QL, SP), UPTRAVI (PA, QL, SP). Sources: [[chunk 144]], [[chunk 152]], [[chunk 153]]

    Formulary tiering and restrictions

    Medications are assigned coverage tiers and may have PA, QL, age limits, or specialty flags as indicated below.

    Tier and restriction assignment: Each product entry includes a Tier Level and may include one or more restrictions such as Quantity Limits (QL), Prior Authorization (PA), Age Limits (AL), Split Fill (SF), Specialty handling (SP), or ME90 (morphine-equivalent) notations. Prescribers and pharmacies must follow the entry-specific restrictions for coverage.

    Examples: alprazolam entries with QL; EMSAM patch with PA and 90-day mail flag; aripiprazole long‑acting injectables with PA and QL. Sources: [[chunk 180]], [[chunk 186]], [[chunk 193]]

    General coverage conditions

    Coverage is subject to product-specific utilization management as listed below

    Formulary access conditions: Access to a listed product requires adherence to the product-specific controls shown in the formulary entry (e.g., obtain PA when 'PA' is indicated; do not exceed QL; abide by AL where specified; use specialty channel when 'SP' is shown). Failure to comply may result in denial of coverage or requirement for an exception request.

    Sources: [[chunk 198]], [[chunk 212]]

    Per-product coverage controls

    Coverage and utilization controls are applied per-product; common controls include:

    Formulary control application: Products are assigned controls such as QL (quantity limits), PA (prior authorization), SP (specialty), SF (split fill), ST (step therapy), AL (age limit), 90 (90-day mail supply), and ME90 (morphine equivalent flag). Coverage and dispensing must follow the specific control(s) listed on the product entry.

    Sources: [[chunk 218]], [[chunk 220]], [[chunk 233]]

    Coverage conditioned on per-product utilization controls

    Products listed with assigned tier levels and specific utilization management actions; coverage conditioned on meeting any listed control (PA/QL/SP).

    Coverage condition: For each listed drug, coverage is conditioned on fulfillment of any inline utilization controls (e.g., if the entry lists PA, an approved prior authorization is required; if QL is listed, the dispensed quantity must not exceed the limit unless an exception is authorized).

    Examples and legends appear in the drug list; see specific entries for the exact controls. Sources: [[chunk 252]], [[chunk 260]], [[chunk 271]]

    The formulary explicitly lists categories that are not covered. Examples include anorexia/weight loss or gain drugs, bulk chemicals, cosmetic enhancing drugs, diagnostic agents, DESI (Drug Efficacy Study Implementation) drugs, experimental or investigational drugs, fertility drugs, general anesthetic drugs, erectile dysfunction drugs prescribed to treat impotence, opioid cough and cold products (excluded for ages <18), over‑the‑counter products not on the plan drug list, and surgical supplies/medical devices.

    In the provided vaccine and related product segments there are no additional broad exclusion categories stated; entries focus on product‑level controls such as quantity limits (e.g., SHINGRIX QL = 2 per lifetime) and tier assignments rather than an explicit exclusion list in these chunks.

    These formulary product segments do not contain a separate, overarching exclusions statement. Coverage descriptors are presented as per‑product annotations (e.g., PA, QL, SP, SF) and no explicit exclusions language appears in these chunks.

    Within this cardiology/related drug listing excerpt no distinct exclusions list is provided. The text indicates per‑product operational flags (for example, mail‑order day supply markers) but does not enumerate excluded categories in these chunks.

    This section lists per‑product quantity limits and tiering for CNS agents but contains no explicit statement declaring additional excluded drug categories; controls are applied at the product level (e.g., QL) rather than via an exclusions list in this excerpt.

    The long‑acting injectable and mood‑stabilizer listings describe utilization controls (for example, PA and QL for INVEGA TRINZA) but do not include a separate exclusions enumeration in this excerpt.

    The prenatal vitamins and minerals segment lists product entries and any product‑level limits; it does not present an explicit exclusions list within these chunks.

    No 'not medically necessary' determinations are stated in these product listing chunks; the content is limited to formulary flags (e.g., PA, QL, SP) and quantity/tier information without explicit NMN language.

    The respiratory/inhaled therapy excerpts include age‑based PA and quantity limits but do not contain explicit 'not medically necessary' findings; restrictions are described as utilization controls rather than NMN determinations.

    In this excerpt of CNS product entries there are no explicit 'not medically necessary' determinations; the entries specify tiering and quantity limits (QL) instead of NMN language.

    The antipsychotic/long‑acting injectable listings indicate PA and QL requirements but do not include explicit statements labeling therapies as 'not medically necessary' within these chunks.

    The minerals, prenatal vitamin and related listings show product‑level information and necessary actions but do not present explicit 'not medically necessary' statements in the provided segments.

    Formulary Product Listings, Flags, and Key Values

    Formulary products listedmixed
    GENVOYAelvitegrav-cobic-emtricitab-tenofov af tab 150-150-200-10 mg
    ISENTRESSraltegravir potassium tabs/chew/packet (various strengths)
    JULUCAdolutegravir sodium-rilpivirine hcl tab 50-25 mg
    KALETRAlopinavir-ritonavir soln/tab (various strengths)
    lamivudineoral solution and tablets (Epivir) 10 mg/ml, 150 mg, 300 mg
    maravirocSelzentry tabs/solution 150 mg, 300 mg; oral soln 20 mg/ml
    NEVIRAPINEnevirapine susp/tab (Viramune)
    NORVIRritonavir powder packet 100 mg
    STRIBILDelvitegrav-cobic-emtricitab-tenofovdf tab 150-150-200-300 mg
    SUNLENCA / YEZTUGOlenacapavir sodium tab 300 mg (therapy packs and single tablets)
    1–10 of 24
    1/3
    Selected Vaccine EntriesmixedCovered
    FLUZONE HIGH-DOSE 2025-2026influenza virus vac split high-dose pf susp pref syr 0.5ml
    FLUZONE 2025-2026influenza virus vaccine split im susp
    GARDASIL 9human papillomavirus (hpv) 9-valent recomb vac
    HAVRIXhepatitis a vaccine susp prefilled syr
    HEPLISAV-Bhepatitis b vaccine recomb adjuvanted pref syr 20 mcg/0.5ml
    Additional Vaccine EntriesmixedCovered
    SHINGRIXzoster vac recombinant adjuvanted for im inj 50 mcg/0.5ml
    SPIKEVAXcovid-19 mrna vaccine-moderna im susp pref syr 50 mcg/0.5ml
    PNEUMOVAX 23pneumococcal vaccine polyvalent soln pref syr 25 mcg/0.5ml
    Selected Specialty/Cancer DrugsmixedCovered
    abiraterone acetate 250 mg (Zytiga)oral tablet - oncology
    ALECENSAalectinib hcl cap 150 mg
    AUGTYROrepotrectinib cap 40 mg / 160 mg
    IBRANCEpalbociclib cap/tab 75/100/125 mg
    IMBRUVICAibrutinib cap 140 mg / oral suspension
    dasatinib (Sprycel)dasatinib tabs various strengths
    Formulary drug entries from excerptmixed
    gefitinib tab 250 mgIressa; Tier Level = 1; QL (30 tablets/30 days), SF, SP
    afatinib dimaleate tab 20 mg, 30 mg, 40 mgGILOTRIF; Tier Level = 2; QL (30 tablets/30 days), SP
    mirdametinib cap/tab 1-2 mgGOMEKLI; Tier Level = 2; QL varying (168 tablets/28 days or 84 capsules/28 days), SP
    topotecan hcl cap 0.25 mg, 1 mgHYCAMTIN; Tier Level = 2; SP
    hydroxyurea cap 500 mgHydrea; Tier Level = 1
    palbociclib cap/tab 75 mg, 100 mg, 125 mgIBRANCE; Tier Level = 2; QL (21 caps/tablets/28 days), SP
    taletrectinib adipate cap 200 mgIBTROZI; Tier Level = 2; QL (90 capsules/30 days), SP
    ponatinib hcl tab 10 mg, 15 mg, 30 mg, 45 mgICLUSIG; Tier Level = 2; QL (30 tablets/30 days), SF, SP
    imatinib mesylate tab 100 mg, 400 mgGleevec; Tier Level = 1; QL (90 tablets/30 days for 100 mg; 60 tablets/30 days for 400 mg), SF, SP
    ibrutinib cap/oral susp 140 mg / 70 mg/mlIMBRUVICA; Tier Level = 2; QL (90 caps/30 days or 216 mL/30 days), SP
    1–10 of 20
    1/2
    Formulary drug list (partial)NDC | mixed
    drug names and strengthsMultiple listed products with strengths (e.g., TAGRISSO - osimertinib 40 mg, 80 mg; TALZENNA - talazoparib 0.25 mg ...)
    Formulary flags and quantity limitsmixed
    QL (360 tablets/30 days)acarbose 25 mg — quantity limit
    QL (180 tablets/30 days)acarbose 50 mg — quantity limit
    QL (90 tablets/30 days)acarbose 100 mg — quantity limit
    STStep therapy flag (appears on alogliptin products and others)
    9090 days available at mail order
    QL (30 tablets/30 days)alogliptin formulations — quantity limit
    QL (60 tablets/30 days)alogliptin-metformin formulations — quantity limit
    QL (6 packs/365 days)Baqsimi nasal glucagon — quantity limit
    DXDiagnosis required (e.g., liraglutide, OZEMPIC)
    PAPrior authorization required
    1–10 of 19
    1/2
    Formulary drug list (no billing codes present)mixed
    N/ADrug names and strengths listed (no CPT/HCPCS/ICD codes in these chunks)
    No procedure/diagnosis codes in this sectionmixed
    No codes listed
    Drug listings (no procedure/diagnosis codes in this excerpt)NDC | mixed
    No codes listed
    Formulary product list (partial)mixed
    INVEGA TRINZA - paliperidone palmitate er susp pref syr 273 mg/0.88ml, 410 mg/1.32ml, 546 mg/1.75ml, 819 mg/2.63mlTier Level = 2; PA, QL (1 syringe/84 days)
    lurasidone hcl tab 20 mg, 40 mg, 60 mg, 120 mg (Latuda)Tier Level = 1; QL (30 tablets/30 days), 90
    paliperidone tab er 24hr 1.5 mg, 3 mg, 9 mg (Invega)Tier Level = 1; PA, QL (30 tablets/30 days), 90
    quetiapine fumarate tab er 24hr 50 mg, 300 mg, 400 mg (Seroquel xr)Tier Level = 1; PA, QL (60 tablets/30 days), 90
    REXULTI - brexpiprazole tab 0.25 mg to 4 mgTier Level = 2; PA, QL (30 tablets/30 days), 90
    risperidone microspheres for im extended rel susp (Risperdal consta) 12.5 mg to 50 mgTier Level = 1; PA, QL (2 vials/28 days)
    UZEDY - risperidone subcutaneous er susp pref syr 50 mg to 125 mg and 150 mg to 250 mgTier Level = 2; PA, QL (1 syringe/28 or 56 days)
    VERSACLOZ - clozapine susp 50 mg/mlTier Level = 2; PA, QL (540 mls/30 days)
    VRAYLAR - cariprazine hcl cap 1.5 mg to 6 mgTier Level = 2; PA, QL (30 capsules/30 days), 90
    ZYPREXA RELPREVV - olanzapine pamoate for extended rel im susp 210 mg, 300 mg, 405 mgTier Level = 2; PA, QL (1-2 vials/28 days)
    1–10 of 18
    1/2
    Formulary control codes / legendmixed
    ME90Morphine Equivalent
    PAPrior Authorization
    QLQuantity Limits
    SPSpecialty
    ALAge Limit
    STStep Therapy
    Formulary legends and control codesmixed
    PAPrior Authorization
    QLQuantity Limits
    SPSpecialty
    ALAge Limit
    STStep Therapy
    DXDiagnosis Required
    9090 days available at mail order
    SFSplit Fill
    ME90Morphine Equivalent
    inv-33: Morphine Equivalent daily limit
    Morphine Equivalent daily limit>= 90 mg per day
    ME designation used in formularyME90 (morphine-equivalent notation) applied to opioid products
    Prior authorization for >ME90If daily dose is above ME90, prior authorization is required
    inv-34: Opioid naive initial IR supply
    Opioid‑naive initial IR supply7 days
    Refill thresholdAll opioids subject to 75% refill threshold (75% of original fill must be used before second fill)
    ER opioid requirementER opioids require history of IR opioids or prior authorization
    inv-35: Lifetime dose limit example
    Lifetime dose exampleABRYSVO = 1 dose per lifetime
    Applies to vaccinesSome immunizing agents have lifetime QLs as listed
    Claims must reflect QLPharmacy claims should match listed quantity/time period
    inv-36: Annual quantity example
    Annual quantity exampleSUNLENCA / YEZTUGO = 4 tablets per 365 days
    Applies to lenacapavir therapy packsTherapy packs and single tablets listed with annual QL
    Claims guidanceClaims should reflect the listed per‑year quantity limit
    inv-37: 30-day supply examples
    30‑day supply example (combo antivirals)GENVOYA = 30 tablets/30 days
    Other 30‑day examplesSTRIBILD, SYMTUZA, VIREAD listed as 30 tablets/30 days where specified
    Quantity limits vary by formulationSee per‑product QL for packets, tablets, mLs or syringes
    inv-38: SHINGRIX lifetime limit
    SHINGRIX lifetime limit2 vaccines per lifetime
    Vaccine QL notationVaccines list QL and may include age limits (AL) where applicable
    Claims and exceptionsRequests exceeding vaccine QL may require a quantity‑limit exception
    inv-39: Example quantity limits
    Examples of tablet/capsule QLse.g., QL 30 tablets/30 days; QL 120 tablets/30 days; QL 240 tablets/30 days depending on drug
    High QL oncology examplesTAFINLAR listed with QL up to 840 tablets/28 days for certain presentations
    Formulation‑specific QLsSome drugs list capsule vs tablet vs mL limits per 30 days or other period
    inv-40: Quantity limits examples
    Mixed QL examples (capsules/mLs)VITRAKVI = QL 300 mls/30 days (oral solution) and capsule QLs by strength; VENCLEXTA QLs vary by strength
    Split fill and specialty flagsMany high‑cost agents include SF and SP designations affecting QL behavior
    Mail order 90‑day option90‑day mail supply available for many oral products as noted
    inv-41: Quantity limits examples (specialty biologics etc.)
    High‑volume specialty QLsOctreotide acetate: QL 90 syringes/30 days or QL 90 mLs/30 days or QL 90 vials/30 days (prefilled syringe, vial, mL formulations)
    Repatha examplesREPATHA prefilled syringe = 2 syringes/28 days; REPATHA SureClick = 6 pens/28 days
    Octreotide administration formsPrefilled syringes, vials, and mL presentations each have specific QLs
    inv-42: Quantity Limits examples
    Typical tablet QL examplesQL 30 tablets/30 days and QL 60 tablets/30 days appear frequently (e.g., lurasidone QL 30 or 60 tablets/30 days by strength)
    Vial and mL examplesSome injectables list QL 2 vials/28 days or large mL limits (e.g., 540 mls/30 days) depending on product
    Claims should match QL/day supplyPharmacy claims must include product and days' supply consistent with listed QL
    inv-43: Quantity limits examples
    Examples including pens and syringesExamples include 2 syringes/28 days, 6 pens/28 days, 30 tablets/30 days, and 90‑day mail‑order supply
    Titration kits and package QLsSome therapies (e.g., ORENITRAM) list titration kit limits like 1 package/180 days
    Dose‑pack timingQuantity limits may be specified over 28, 30, 180, or 365 day intervals depending on product
    inv-44: Quantity limits examples
    Long‑acting injectable QLsExamples: QL 1 syringe/28 days, QL 1 syringe/56 days, QL 1 syringe/84 days for LAI antipsychotics
    Specific productsINVEGA TRINZA = 1 syringe/84 days; ABILIFY MAINTENA = 1 syringe/28 days; ARISTADA formulations vary (28–56 days)
    PA appliesMany LAI products are PA‑required in addition to QL limits
    inv-45: Mail-day supply
    Mail‑day supply note90 days available at mail for many oral products
    90‑day indicator in legend'90' denotes 90‑day mail‑order supply availability as shown in legend
    Apply to claimsClaims should reflect mail‑order day‑supply where applicable
    inv-46: Quantity Limits examples
    Biologic/specialty QL group examplesAdalimumab‑class and other biologics list QLs such as 2 syringes/28 days (adalimumab) or 4 syringes/28 days (Enbrel)
    Migraine biologicsAIMOVIG = 1 syringe/28 days; EMGALITY prefilled syringes = 9 syringes/180 days; AJOVY = 3 syringes/84 days
    Specialty handlingThese agents are often SP‑designated and may require specialty pharmacy processing and PA
    inv-47: BERINERT quantity limit
    BERINERT quantity limit10 vials per 30 days
    Applies to coagulation factorsMany factor products carry PA and SP designations in addition to QLs
    Quantity‑limit exceedance riskExceeding stated QL may result in denial without PA
    inv-48: HAEGARDA quantity limits
    HAEGARDA quantity limits27 vials/28 days and 18 vials/28 days depending on presentation
    PA and SP applyHAEGARDA is PA‑required and SP‑designated
    Claims implicationsRequests exceeding vial limits may be denied without authorization
    inv-49: Enoxaparin QL
    Enoxaparin QL30 prefilled syringes per 365 days
    Prefilled syringe presentationsEnoxaparin prefilled syringes listed with annual syringe limit
    Specialty/PA notesSome anticoagulant/antithrombotic products carry additional PA or SP flags

    Prior Authorization, Step Therapy, Documentation, and Denial Risks

    Prior Authorization

    Prior authorization required for PA‑marked and specialty drugs

    Certain medications listed on the drug list that are annotated with the code 'PA' require prior authorization before BCBSNM will cover the drug; specialty drugs also require prior authorization and must be obtained from a participating specialty supplier (Accredo preferred). If prior authorization is not obtained, BCBSNM may not pay for the drug.

    • PA appears in the 'Necessary actions, restrictions, or limits on use' column to indicate prior authorization is required.
    • Specialty drugs require PA and must be filled by an in‑network specialty supplier (Accredo preferred); limited distribution pharmacies may be used if Accredo cannot supply.
    Prior Authorization

    Obtain PA when 'PA' or 'SP' is indicated

    Products flagged with 'PA' or with specialty designation ('SP') in the formulary legend will trigger prior authorization and specialty pharmacy workflows; providers must obtain authorization per plan rules before dispensing.

    • PA and SP flags in the formulary legend indicate required authorization or specialty handling.
    • Examples in the list (e.g., CAYSTON) show SP with QL and PA where applicable.
    Prior Authorization

    Prior authorization applies where PA/SP flags appear

    Where a product is annotated with 'PA' or 'SP' next to the drug entry, prior authorization must be obtained; the formulary legend uses these flags to indicate the need for authorization or specialty routing.

    • Legend abbreviations include PA = Prior Authorization and SP = Specialty.
    • When 'PA' appears in the product entry, prior authorization is required before coverage is approved.
    Prior Authorization

    Obtain prior authorization when 'PA' is indicated

    If 'PA' is present in the 'Necessary actions, restrictions, or limits on use' column for a product, providers must obtain prior authorization before BCBSNM will cover the drug; failure to get PA may result in non‑payment.

    • PA is the formulary marker that indicates prior authorization is required for coverage.
    • Contact Member Services for instructions on submitting a PA or use the coverage exception form on MyPrime.com.
    Prior Authorization

    Prior authorization required for listed PA drugs (examples)

    Many listed drugs explicitly include 'PA' in their product entry (examples across the list); providers must secure prior authorization for those listed agents before dispensing.

    • Examples: danazol and various testosterone products are listed with PA.
    • Agents such as liraglutide (Victoza), OMNITROPE, ACTHAR, MYALEPT, and ORILISSA are annotated PA in their entries.
    Prior Authorization

    PA required for select specialty/brand agents (Victoza, somatropin, ACTHAR)

    Specific high‑cost and specialty agents in the formulary are listed with PA; providers must obtain prior authorization for these medications (examples include liraglutide/Victoza, somatropin/OMNITROPE, and ACTHAR).

    • Victoza (liraglutide) — DX, PA, QL noted in entry.
    • OMNITROPE (somatropin) and ACTHAR are shown with PA and SP where applicable.
    Prior Authorization

    Prior authorization required for multiple specialty products

    Multiple specialty products and biologics are annotated 'PA' in the drug list; providers must secure prior authorization for these specialty agents prior to coverage (examples include MYALEPT, ORILISSA, sapropterin/Kuvan, tolvaptan/Samsca, REPATHA).

    • These entries show PA and often SP and QL alongside the product.
    • Providers should confirm PA requirements for each formulation listed.
    Prior Authorization

    PA for selected psychotropic and long‑acting injectable products

    Prior authorization is required for certain specialty and psychotropic products and for long‑acting injectable antipsychotics where 'PA' appears in the entry (examples include EMSAM, FETZIMA, ABILIFY ASIMTUFII, ARISTADA, INVEGA SUSTENNA/TRINZA).

    • Long‑acting injectables list PA and specific QLs (e.g., 1 syringe/28 days or 1 syringe/84 days for INVEGA TRINZA).
    • Brand/ER formulations may also be annotated PA.
    Prior Authorization

    PA required for numerous listed products (examples)

    The formulary contains many PA‑marked products across therapeutic classes; providers must obtain prior authorization for those items before BCBSNM will cover them.

    • Examples include REPATHA (PA, QL), ADEMPAS, ambrisentan, bosentan, ORENITRAM, TYVASO, UPTRAVI which show PA in their entries.
    • Check each product entry for PA and associated QL or SP requirements.
    Prior Authorization

    PA required for PA‑marked products (QVAR RediHaler, TRELEGY)

    Products marked 'PA' in the formulary (e.g., QVAR RediHaler, TRELEGY ELLIPTA) require prior authorization; providers should obtain PA and note any age‑based PA where indicated.

    • QVAR REDIHALER entries include PA (>=12 yr) and QL requirements.
    • TRELEGY ELLIPTA is listed with PA and QL (1 inhaler/30 days).
    Prior Authorization

    PA required for selected psychotropic and LA injectables

    Selected psychotropic brand products and long‑acting injectable antipsychotics require prior authorization as indicated by PA next to the product; obtain PA before dispensing to avoid coverage denial.

    • Examples include EMSAM (PA), ARISTADA (PA, QL), ABILIFY MAINTENA (PA, QL).
    Prior Authorization

    Obtain PA for age‑limited products

    Many products include age‑based PA notations; where age limits or age‑based PA appear (e.g., PA (<=5 yr), PA (<=17 yr)), providers must obtain prior authorization in accordance with those age restrictions.

    • Aripiprazole products show PA (<=5 yr) for some formulations; multiple other agents have AL or age‑based PA noted.
    • Failure to obtain required age‑based PA may result in denial.
    Prior Authorization

    Opioid PA tied to ME90 and opioid limits

    Opioid products are annotated with ME90 (morphine equivalent) and, when dosing exceeds ME90 or other opioid limits apply, prior authorization is required; opioid‑naive initial IR supply limits also apply.

    • ME90 = current daily morphine equivalent limit of 90 mg per day in New Mexico; doses above ME90 require PA.
    • Opioid‑naive members are limited to a seven‑day supply of immediate‑release opioids for their first fill.
    Prior Authorization

    PA required for migraine biologics and other specialty biologics

    PA is required for certain specialty biologics including multiple migraine preventive biologics; providers must obtain PA for agents such as AIMOVIG, AJOVY, and EMGALITY before coverage.

    • AIMOVIG, AJOVY, EMGALITY entries show PA and specific QLs (e.g., AIMOVIG QL 1 syringe/28 days; EMGALITY QL 1 syringe/28 days or 9 syringes/180 days).
    • Lack of PA for these specialty biologics may result in non‑coverage.
    Prior Authorization

    PA applies to listed specialty and brand products (examples)

    Prior authorization applies to many brand and specialty products listed with 'PA' in their entry; providers must obtain PA for those products (examples include EMGALITY products, LAMICTAL XR kits, certain hormone and metabolic agents).

    • EMGALITY prefilled syringes and auto‑injectors show PA and QL requirements.
    • LAMICTAL XR starter kits are noted with PA in product entries.
    Prior Authorization

    PA required for many specialty/injectable and factor products

    Many injectable, high‑cost, or specialty factor products are annotated 'PA' and 'SP'; providers must obtain prior authorization for these specialty/injectable products prior to dispensing (examples: ADVATE, ADYNOVATE, HAEGARDA, BERINERT).

    • Hemophilia and coagulation factors (ADVATE, ADYNOVATE, ALPHANATE, ALPHANINE SD) list PA and SP.
    • HAEGARDA and BERINERT show PA with specific QLs.
    Step Therapy

    Step therapy applies where 'ST' is marked; request exceptions if unmet

    Some drugs are subject to step therapy (marked 'ST'); if the required step therapy has not been met, providers or members may request a step therapy exception through Member Services.

    • Step therapy is identified by 'ST' in the formulary and requires trying specified first‑line agents before coverage for later agents.
    • To request an exception, contact BCBSNM Member Services at 1‑866‑689‑1523.
    Step Therapy

    Confirm step therapy for ST‑flagged products

    The formulary marks some drugs/classes with 'ST' (step therapy); providers must confirm and meet step therapy requirements for products annotated with ST before coverage is approved.

    • Examples: alogliptin products and certain SGLT2/DPP‑4 combinations are shown with ST.
    • Legend includes ST = Step Therapy to indicate where step edits apply.
    Step Therapy

    ST legend: step therapy indicated where 'ST' appears

    The formulary legend defines 'ST = Step Therapy'; when ST appears next to a product, step therapy requirements must be followed though specific per‑drug step sequences are not listed in this excerpt.

    • ST is part of the formulary abbreviation legend and indicates a step requirement may apply.
    • Providers should review product entries and contact Member Services for step‑therapy details or exception processes.
    Prior Authorization

    PA and age/Q L requirements for select inhaled products

    When 'PA' is shown next to specific drugs (e.g., QVAR RediHaler, TRELEGY ELLIPTA), providers must obtain prior authorization and observe any age limits or QLs noted in the entry.

    • QVAR REDIHALER entries indicate PA (>=12 yr) and specific QLs (1–2 inhalers/30 days).
    • TRELEGY ELLIPTA is listed PA with QL (1 inhaler/30 days).
    Step Therapy

    ST applies to specific agents (e.g., alogliptin, STEGLATRO)

    Step therapy is referenced in the formulary legend and applies to some products (examples: alogliptin products, STEGLATRO/ertugliflozin) where ST appears; providers must follow step edits where applied.

    • Alogliptin and its combinations are annotated ST and QL in product entries.
    • STEGLATRO entries include ST for certain strengths.
    Step Therapy

    Step therapy required for select DPP‑4/SGLT2 and combination agents

    Step therapy requirements are shown for several combination and DPP‑4/SGLT2 agents (e.g., alogliptin products, ertugliflozin/Steglatro); providers must confirm the member has met required prior steps or request an exception.

    • Entries indicate ST alongside QL and 90‑day mail flags where applicable.
    • If step therapy is unmet, contact Member Services for exception procedures.
    Step Therapy

    Legend notes ST = Step Therapy; check product specifics

    The formulary legend includes ST = Step Therapy, but specific step‑by‑step rules for individual drugs are not provided in this excerpt; providers should check product entries or contact Member Services for details.

    • ST appears across the legend and multiple product entries but per‑drug step sequences are not shown here.
    • Providers may need to query plan resources for the exact step pathway.
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Documentation Required

    How to submit prior authorization (fax/phone/online)

    Providers may submit prior authorization (coverage exception) requests by fax to 1‑877‑243‑6930, by phone to 1‑800‑285‑9426 (TTY/TDD 711), or online via MyPrime.com or CoverMyMeds.com.

    • Use the coverage exception request form available on MyPrime.com.
    • Phone and fax options are provided for prescribers to submit PA requests.
    Note

    Contact Member Services for PA/coverage questions

    For questions about drug coverage, authorization processes, or to initiate exceptions, members or providers should contact BCBSNM Member Services at 1‑866‑689‑1523 (TTY/TDD 711).

    • Member Services is available Monday–Friday, 8:00 a.m. to 5:00 p.m. Mountain time.
    • Member Services can advise on PA, step therapy exceptions, or quantity‑limit exceptions.
    Billing Rule

    Ensure claims reflect listed QL and day‑supply

    Pharmacy claims must reflect the product and days' supply consistent with the listed quantity limits (QL) and mail‑day supply rules; submitting claims that exceed QL or incorrect day‑supply may lead to denial or adjustment.

    • Examples: GENVOYA QL (30 tablets/30 days); many oral products have 90‑day mail‑order availability noted.
    • Claims should use the days' supply and quantity that match the formulary QL.
    Documentation Required

    Specialty drugs: follow QL and SP handling

    Specialty‑designated products (SP) must follow the specialty dispensing and quantity‑limit rules; providers should expect specialty pharmacy handling, documentation, and routing for SP products.

    • Specialty drugs are handled through the BCBSNM network specialty supplier (Accredo preferred).
    • SP entries often include QL and PA requirements; follow specialty pharmacy submission processes.
    Documentation Required

    Provide required documentation for flagged controls (PA, DX, SP, etc.)

    Formulary entries use shorthand flags (PA, QL, SF, SP, ST, DX, AL) to indicate required administrative controls; providers must supply required documentation when those flags appear (e.g., DX = diagnosis required, PA = prior authorization).

    • DX indicates a diagnosis is required for coverage.
    • SF indicates split‑fill; ST indicates step therapy; AL indicates age limits.
    Note

    Refer to formulary legend for PA/QL/SP/ST/DX/AL meanings

    The formulary legend defines operational abbreviations used across entries (PA = Prior Authorization, QL = Quantity Limits, SP = Specialty, ST = Step Therapy, DX = Diagnosis Required, AL = Age Limit, 90 = 90‑day mail order).

    • Use the legend to interpret per‑product controls and submission needs.
    • These abbreviations indicate actions that must be completed to secure coverage.
    Documentation Required

    Supply diagnosis documentation when 'DX' or PA is required

    Products annotated 'DX' require an associated diagnosis to be documented when seeking PA or coverage; prescribers must supply diagnosis documentation where 'DX' appears.

    • Examples: Victoza and other agents include DX with PA and QL flags where diagnosis may be needed.
    • Documentation supporting the clinical indication should be included with PA requests.
    Documentation Required

    Prescribers must supply clinical documentation for PA

    For drugs marked 'PA' providers must submit supporting clinical documentation to meet the prior authorization requirements (examples: ADEMPAS, ambrisentan, bosentan, ORENITRAM, TYVASO, UPTRAVI).

    • Include clinical rationale and any prior step failures or contraindications when requesting PA.
    • Member Services or the PA submission portals can confirm required documentation elements.
    Note
    Note
    Documentation Required

    Obtain PA prior to dispensing; observe age‑based PA notes

    For products marked 'PA' the provider must obtain prior authorization before dispensing; age‑based PA notes appear for some products (e.g., PA (<=5 yr) for certain aripiprazole formulations, PA (<=17 yr) for some opioid entries).

    • Aripiprazole products list PA with specific pediatric age limits.
    • Opioid entries include ME90 and PA (<=17 yr) for certain formulations.
    Denial Risk

    Risk of denial for exceeding quantity limits (QL)

    Claims that exceed stated quantity limits (QL) are at risk for denial or require a quantity‑limit exception; providers should confirm QL in the product entry and request a QL exception if clinically necessary.

    • Examples of QL exceedance risks: QL 90 syringes/30 days, QL 2 syringes/28 days, QL 240 capsules/30 days.
    • SHINGRIX is limited to QL 2 vaccines per lifetime.
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Denial Risk

    Denial risk if PA or specialty requirements are not met

    Coverage may be denied when a drug is designated PA or SP and the necessary prior authorization or specialty authorization is not obtained; providers should secure PA for PA‑marked products to avoid denial.

    • PA+SP entries (e.g., Repatha, ORENITRAM) require authorization and adherence to QL/SP rules.
    • Failure to obtain PA for PA‑marked drugs may lead to non‑coverage.
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note

    Initial Therapy and Specialty Split-Fill

    Specialty Split Fill — Specialty Pharmacy Split Fill Program for new specialty drug starts

    Specialty Pharmacy Split Fill Program for new specialty drug starts

    Split fill dispensing: When a specialty drug is labeled 'SF' as a new start, the Specialty Pharmacy Split Fill Program provides two 14- or 15-day supplies each month for the first two to three months to establish tolerability and dosing and to reduce waste; after dose is established, standard monthly dispensing may resume.

    Source: [[chunk 12]]

    Long-acting injectables — selected long-acting injectable and ER antipsychotics

    Selected long-acting injectable and extended release antipsychotics

    LAI antipsychotics: Long‑acting injectable (LAI) antipsychotics listed require Prior Authorization when 'PA' is indicated and are subject to specified quantity limits reported per dosing interval (e.g., QL per 28, 56, or 84 days). Administration/dispensing follows the product entry (some products are SP) and claims must reflect the listed quantity/day‑supply.

    Examples: ABILIFY MAINTENA, ARISTADA, INVEGA TRINZA, RISPERDAL CONSTA, UZEDY — see individual entries for PA and QL values. Sources: [[chunk 193]], [[chunk 198]], [[chunk 201]], [[chunk 203]]

    Step Therapy Controls and Notation

    Coverage labelDescription
    ST
    Step therapy applies to some drugs identified by 'ST' in the drug list; medications subject to step therapy are identified by an 'ST' in the 'Necessary actions, restrictions, or limits on use' column and must meet required prior steps or obtain an exception for coverage.
    FlagMeaning / use in formulary
    ST
    Indicates the product is subject to Step Therapy; listed next to specific drug formulations where the plan requires trying specified first-line agents before covering the listed agent.
    Legend codeDefinition
    ST
    ST = Step Therapy (appears in the formulary legend as a possible utilization control).
    ProductST noted?
    Alogliptin (e.g., alogliptin, alogliptin/metformin, alogliptin/pioglitazone)
    Yes — entries include 'ST' alongside QL and 90-day mail flags for alogliptin formulations.
    ObservationSource notes
    ST appears in the legend as an available control
    Multiple legend excerpts show ST = Step Therapy, but this document excerpt does not include full, drug-specific step-path requirements or step-edit logic.
    ProductST flag present?
    Alogliptin (alogliptin benzoate and combinations)
    Marked with ST in formulary entries (ST present with QL and 90 flags).
    Agent / classStep therapy requirement (as shown)
    Alogliptin products
    Listed with QL and ST — step therapy applies prior to coverage unless an exception is obtained.
    Legend entryImplication
    ST = Step Therapy
    Legend shows ST as a control code; no step paths or detailed algorithm are provided in this excerpt.
    ReferenceContent
    Formulary legend examples
    Abbreviations listed in legend include ST = Step Therapy alongside PA, QL, SP, SF, AL, DX, 90, and ME90.
    ReferencePolicy statement
    Step therapy as a control
    When a drug is subject to step therapy (ST), members or providers may request a step therapy exception via Member Services if required steps have not been met.
    Legend codeInterpretation
    ST
    Step Therapy (ST) is referenced in the formulary legend as an available utilization control; specific step requirements are not enumerated here.
    Legend itemNote
    ST = Step Therapy
    Listed with other control codes; treatment exceptions and Member Services contact information are provided elsewhere for ST exceptions.
    NotationPresence in excerpt
    ST
    Step therapy notation appears repeatedly in legend excerpts but no per-drug step paths are included in these chunks.
    Legend/codeComment
    ST
    Defined in the legend as Step Therapy; the excerpt does not show the detailed step requirements for specific drugs beyond flagging (e.g., alogliptin entries show ST).
    LegendDetail level
    ST = Step Therapy
    Legend includes ST but the document excerpt does not provide step sequences or decision logic for ST-marked agents.

    Quantity Limits and Day-Supply Examples

    inv-187: unspecified example quantity-limit applies to certain drugs
    Unspecified example QLDocumented example: no more than 60 tablets for 30 days (varies by drug)
    QL identificationDrugs with quantity limits are marked 'QL' in the drug list
    Exception processMembers/providers can request a quantity‑limit exception via Member Services
    inv-188: AZITHROMYCIN TABS quantity limit example
    AZITHROMYCIN tabs QLAzithromycin tablets = QL 60 tablets/180 days
    Formulation notesSuspensions listed without this QL; tablets have the specific 60/180 limitation
    Legend codesQL and other abbreviations shown in formulary legend apply
    inv-189: TOBRAMYCIN NEBU SOLN (TOBI) quantity limit
    TOBRAMYCIN NEBU SOLN (TOBI) QL56 units per 56 days
    Specialty flagTOBI is SP‑designated in some entries
    Claims periodQL specified over 56‑day interval for nebulized units
    inv-190: FLUCONAZOLE suspension quantity limit
    FLUCONAZOLE suspension QL70 mLs per 28 days
    Suspension vs tablet QLsSuspension listed with 70 mLs/28 days while tablets have separate QL
    Tablet exampleFluconazole tablets = QL 30 tablets/30 days
    inv-191: FLUCONAZOLE tablets quantity limit
    FLUCONAZOLE tablets QL30 tablets per 30 days
    Typical antifungal QLsTablet QLs reflect short‑course antifungal dosing limits
    Claims notePharmacy claims should reflect tablet QL and days' supply
    inv-192: ITRACONAZOLE capsule quantity limit
    ITRACONAZOLE capsule QL120 capsules per 30 days
    Formulation specificItraconazole listed with high capsule QL reflecting chronic dosing in some indications
    SP/PASome antifungals may carry SP or PA flags depending on formulation
    inv-193: TERBINAFINE tab 250 mg quantity limit
    TERBINAFINE 250 mg tab QL90 tablets per 365 days
    Annual QL for terbinafineQL specified over 365‑day period for 250 mg tablets
    Indication tie‑inQL aligns with typical course durations for dermatophyte infections
    inv-194: GENVOYA quantity limit example
    GENVOYA QL30 tablets per 30 days
    Combination product QLsMany antiretroviral combos use 30/30 tablet limits
    Claims guidanceClaims must reflect the QL and corresponding days' supply
    inv-195: ISENTRESS formulations quantity limits
    ISENTRESS formulations QLsISENTRESS QLs vary by formulation: 60–180 units depending on formulation
    Packet vs tablet limitsPackets listed with 60 packets/30 days; chewables and tablets vary
    Formulary notationQL indicates per‑30‑day limit for each formulation
    inv-196: SUNLENCA / YEZTUGO quantity example
    SUNLENCA / YEZTUGO QL4 tablets per 365 days (therapy pack examples)
    Therapy pack detailsEntries list therapy pack sizes and corresponding annual limits
    HIV therapy QLsMany HIV agents have 30/30 tablet QLs while long‑acting agents use annual QLs
    inv-197: ABRYSVO lifetime dose example
    ABRYSVO lifetime dose exampleABRYSVO = 1 dose per lifetime
    Vaccine lifetime QLsCertain vaccines (e.g., RSV products) may be limited to a single lifetime dose
    Coverage implicationRequests beyond lifetime limit require exception review
    inv-198: PAXLOVID quantity examples
    PAXLOVID quantity examplesPAXLOVID pack sizes with QL ranging from 11 to 30 tablets per 30 days depending on pack
    Pack variantsExamples include 6x150/5x100 pack (11 tablets), 10x150/10x100 pack (20 tablets), 20x150/10x100 pack (30 tablets)
    Claims and dispensingClaims should reflect pack QL and days' supply as listed
    inv-199: ATOVAQUONE-PROGUANIL (Malarone) quantity limit
    ATOVAQUONE‑PROGUANIL (Malarone) QL30 tablets per 90 days
    Travel medicine QLMalarone limited per 90‑day window as listed
    Formulary entryListed with QL notation in 'Necessary actions' column
    inv-200: SHINGRIX quantity limit example
    SHINGRIX quantity example2 vaccines per lifetime
    Vaccine QL consistencySHINGRIX QL shown inline with other immunizing agents and age limits where applicable
    Coverage noteExceeding this lifetime QL may require prior authorization or exception
    inv-201: various specialty/cancer drugs QLs grouped
    Specialty/cancer drug group QLsNumerous specialty and oncology drugs list specific QLs (e.g., 120 tablets/30 days, 240 capsules/30 days) and are SP‑designated
    Examples includeALECENSA = 240 capsules/30 days; abiraterone = 120 tablets/30 days; many agents include SF and SP flags
    Provider actionsSpecialty dispensing and PA requirements apply for SP items
    inv-202: gefitinib tab 250 mg QL
    gefitinib 250 mg QL30 tablets per 30 days
    SF and SP flagsGefitinib entry includes SF and SP designations in addition to QL
    Tier designationGe fitinib listed Tier 1 in this segment
    inv-203: imatinib mesylate tab 100 mg QL
    imatinib 100 mg QL90 tablets per 30 days
    Also lists 400 mg presentationImatinib 400 mg QL = 60 tablets/30 days
    SP and SFImatinib entries include SF and SP handling where specified
    inv-204: LYNPARZA olaparib quantity limit
    LYNPARZA (olaparib) QL120 tablets per 30 days
    Applies to multiple strengthsQL applies to listed olaparib tablet strengths (100 mg, 150 mg)
    SF and SP notesEntry includes SF and SP flags indicating specialty handling and potential split fills
    inv-205: SCEMBLIX asciminib quantity limit
    SCEMBLIX (asciminib) QL60 tablets per 30 days
    Oncology specialty QLAsciminib listed with SP and specific monthly QL
    Titrate per labelingProviders should follow labeled dosing and QL when submitting claims
    inv-206: TAFINLAR quantity limit examples
    TAFINLAR examplesTAFINLAR QL examples include 840 tablets/28 days for certain therapy packs and 120 capsules/30 days for other strengths
    Strength‑dependent QLsMultiple presentations carry different QLs depending on strength and pack
    SP designationTAFINLAR entries include SP in addition to QL
    inv-207: VITRAKVI quantity limits
    VITRAKVI QLsOral solution = QL 300 mls/30 days; capsules = QL 180 capsules/30 days or 60 capsules/30 days depending on strength
    Multiple presentation limitsDifferent dosage forms and strengths have distinct QLs
    SP/SF flagsVITRAKVI entries include SF and SP where noted
    inv-208: VENCLEXTA quantity limits by strength
    VENCLEXTA QLs by strengthExamples: 10 mg = 60 tablets/30 days; 50 mg = 30 tablets/30 days; 100 mg = 180 tablets/30 days
    Strength‑based limitsQL varies by tablet strength — consult product line for exact QL per strength
    Claims implicationsEnsure NDC/strength matches QL on claim submission
    inv-209: Contraceptives examples QL
    Contraceptive QL examplesCommon QL for contraceptive tablets = 28 tablets/21 days; longer‑cycle packs show QL per product (e.g., 84 tablets/63 days)
    Patches/ringsSome patches/rings have product‑specific QLs and 90‑day mail options
    Claims noteContraceptive claims should reflect cycle‑based QL and mail‑order availability
    inv-210: acarbose 25 mg QL
    acarbose 25 mg QL360 tablets per 30 days
    acarbose 50 mg QL180 tablets per 30 days
    acarbose 100 mg QL90 tablets per 30 days
    inv-211: acarbose 50 mg QL
    acarbose 50 mg QL180 tablets per 30 days
    Dose forms notedDifferent strengths have proportional QLs per 30‑day period
    Mail‑order 90 optionSome entries include 90‑day mail availability where indicated
    inv-212: acarbose 100 mg QL
    acarbose 100 mg QL90 tablets per 30 days
    Strength‑based QLsHigher strength often has lower tablet QL for same period
    Claims guidanceEnsure strength on claim matches QL listed
    inv-213: liraglutide (Victoza) QL (pens)
    liraglutide (Victoza) QL3 pens per 30 days
    DX/PA flagsVictoza entry includes DX and PA in addition to QL
    Specialty handlingSome GLP‑1 agents require PA and may be SP‑designated
    inv-214: Insulin product QL (mLs)
    Insulin product QL (mLs)Multiple insulin products = QL 45 mLs per 30 days
    Applies to pens and vialsQL applies across pen and vial presentations as listed
    90‑day optionMail‑order 90‑day supply may be available for select insulin products
    inv-215: Glucagon kits QL
    Glucagon kits QL6 packs/kits/pens per 365 days
    Includes Baqsimi, GVOKEMultiple glucagon formulations share the 6/year limit
    Emergency use considerationQL reflects annual replacement needs for rescue kits
    inv-216: Octreotide acetate pref syr QL
    Octreotide acetate pref syr QL90 syringes per 30 days
    Octreotide acetate vials QL90 vials per 30 days (500 mcg vials)
    Alternate mL formulationQL also listed as 90 mLs/30 days for liquid presentations
    inv-218: OZEMPIC (semaglutide) QL
    OZEMPIC (semaglutide) QL1 pen per 28 days
    DX/PA requiredOzempic entries include DX and PA in addition to QL
    Pen‑based dispensingQL reflects single‑pen monthly dispensing
    inv-219: Octreotide acetate formulations QLs (90 syringes/90 mLs/90 vials)
    Octreotide acetate multi‑form QLsQL for octreotide: 90 syringes/30 days OR 90 mLs/30 days OR 90 vials/30 days depending on presentation
    Consistency across formsPolicy lists equivalent monthly limits across syringe, mL, and vial formats
    Specialty handlingThese entries are SP‑designated and may require specialty pharmacy processing
    inv-220: Repatha prefilled syringe QL
    Repatha prefilled syringe QL2 syringes per 28 days
    Repatha SureClick QL6 pens per 28 days for auto‑injector presentation
    PA appliesREPATHA entries are PA‑required in addition to QLs
    inv-221: Repatha SureClick auto-injector QL
    Repatha SureClick auto‑injector QL6 pens per 28 days
    Alternative presentation limitsLimit differs by presentation (syringe vs auto‑injector) as shown
    PA flagPA is noted for Repatha regardless of presentation
    inv-222: ENTRESTO QL examples
    ENTRESTO QL examplesENTRESTO sprinkle caps = QL 240 capsules/30 days; other strengths = QL 60 tablets/30 days
    Age/PA noteENTRESTO sprinkle cap entry includes PA (>=13 yr) in some presentations
    Formulation‑dependent limitsQL differs by formulation (sprinkle vs tablet) as listed
    inv-223: tolvaptan (Samsca) QL (annual)
    tolvaptan (Samsca) annual QLQL 30 tablets/365 days for 15 mg; 60 tablets/365 days for 30 mg
    PA and SPTolvaptan is PA‑required and SP‑designated where listed
    Long‑term QLAnnual QLs reflect restricted chronic use and monitoring requirements
    inv-224: REPATHA summary QL
    REPATHA summary QL2 syringes/28 days or 6 pens/28 days depending on presentation
    PA requiredREPATHA entries include PA in formulary notes
    Specialty handlingSP may apply for certain presentations as indicated
    inv-225: UPTRAVI quantity limits
    UPTRAVI quantity limits60 tablets/30 days or 140 tablets/180 days depending on strength/pack
    PA and SPUPTRAVI entries include PA and SP designations
    Titration packs notedTitration and therapy packs have distinct QLs (e.g., 200 tablets/180 days for titration pack)
    inv-226: ORENITRAM quantity limits and titration kit
    ORENITRAM QLs and titration kitORENITRAM = 300 tablets/30 days; titration kits = 1 package/180 days
    PA and SPORENITRAM entries include PA and SP flags with kit‑based QLs
    Pack‑based limitsTitration kit counts measured per package over 180 days
    inv-227: VYNDAQEL QL
    VYNDAQEL QL120 capsules per 30 days
    PA and SPVYNDAQEL listed with PA and SP designations
    Cardiac vs other indicationsQL applies to tafamidis meglumine (cardiac) presentation as listed
    inv-228: fluticasone-salmeterol QL
    Fluticasone‑salmeterol (Advair) QL60 blisters per 30 days
    Inhaler/blister limitsAdvair listed with blister‑based monthly QL
    90‑day mail option90‑day mail order availability noted in legend where applicable
    inv-229: TRELEGY ELLIPTA QL
    TRELEGY ELLIPTA QL1 inhaler per 30 days
    PA indicatedTRELEGY entries include PA and QL notes in formulary
    Mail‑order 9090‑day mail‑order supply availability appears in legend
    inv-230: KALYDECO packets QL
    KALYDECO packets QL56 packets per 28 days (25 mg packet)
    Packet vs tablet limitsOther packet strengths list different monthly/28‑day QLs
    Specialty handlingKalydeco entries include SP designation
    inv-231: pirfenidone QL
    Pirfenidone QL21 tablets per 180 days for 534 mg tablets (Esbriet)
    Alternate strengthsOther pirfenidone strengths list different QLs (e.g., 180 tablets/30 days for some presentations)
    SP designationPirfenidone entries include SP where indicated
    inv-232: oxybutynin solution QL
    Oxybutynin solution QL600 mLs per 30 days
    Large volume oral solutionsHigh mL limits reflect chronic bladder therapy needs
    90‑day mail optionSome oral solutions may have 90‑day mail availability per legend
    inv-233: ALPRAZOLAM INTENSOL QL
    ALPRAZOLAM INTENSOL QL180 mLs per 30 days (concentrated solution)
    ER tablet QLsAlprazolam ER formulations listed with 30–90 tablets/30 days depending on strength
    Controlled substance limitsMany benzodiazepine listings include QLs and may be subject to additional controls
    inv-234: alprazolam ER tab QL
    Alprazolam ER tablet QLsER tablets listed with QL range 30–90 tablets per 30 days depending on strength
    Immediate vs ER distinctionsDifferent formulations carry distinct QLs and refill rules
    Legend codes90 = mail‑order 90 days option; QL shown per product
    inv-235: EMSAM patch QL and PA
    EMSAM patch QL and PAEMSAM (selegiline TD patch) = QL 90 (mail‑order flag) and PA indicated
    Mail‑order flag meaning'90' denotes 90‑day mail availability for applicable products
    Prior authorization notePA required for EMSAM in addition to QL and mail flag
    inv-236: ABILIFY ASIMTUFII injectable QL
    ABILIFY ASIMTUFII QL1 syringe per 56 days
    LAI antipsychotic QL patternsLong‑acting injectables have QLs expressed in syringes per 28/56/84 days
    PA requiredPA commonly applies to these injectable formulations
    inv-237: Long-acting injectable QLs (MAINTENA/ARISTADA/TRINZA examples)
    LAI injectables QL examplesExamples: ABILIFY MAINTENA/ARISTADA = QL 1 syringe/28 days (some); INVEGA TRINZA = QL 1 syringe/84 days
    Presentation variabilityDifferent LAI products and formulations have distinct QLs and dosing intervals
    Documentation requiredPA and appropriate administration documentation are expected for LAI claims
    inv-238: lurasidone (Latuda) QL
    lurasidone (Latuda) QLQL 30 tablets/30 days (80 mg formulation QL 60 tablets/30 days)
    Strength‑specific QLHigher strength (80 mg) has increased QL allowance per 30 days
    90‑day mail optionLegend indicates 90‑day mail availability where applicable
    inv-239: Mixed examples across list
    Mixed examples across listExamples vary widely (e.g., 30 tablets/30 days; 60 tablets/30 days; 2 vials/28 days; 540 mLs/30 days)
    Large liquid QLsSome oral/solution products list large mL QLs (e.g., gabapentin solution 1500 mLs/30 days)
    Product‑specific rulesCheck per‑product entries for exact QL duration and unit type
    inv-240: butalbital-acetaminophen QL
    butalbital‑acetaminophen QL180 tablets per 30 days
    Common analgesic QLButalbital combinations frequently limited to 180 units/30 days
    Abuse‑mitigation noteHigh QLs for certain analgesics still subject to PA/monitoring per policy
    inv-241: adalimumab-adbm prefilled syringe QL
    adalimumab‑adbm prefilled syringe QL2 syringes per 28 days
    Prefilled syringe kit variantsSome kits/presentations list 1 kit/28 days or 2 pens/28 days depending on format
    SP designationAdalimumab biosimilars are SP‑designated and carry QLs
    inv-242: ENBREL prefilled syringe QL
    ENBREL prefilled syringe QL4 syringes per 28 days
    Multiple ENBREL presentationsENBREL includes syringes, cartridges and auto‑injector presentations with QLs noted
    SP handlingENBREL is SP‑designated for specialty distribution where indicated
    inv-243: AIMOVIG QL
    AIMOVIG QL1 syringe per 28 days
    Migraine biologic patternCGRP inhibitors commonly have monthly syringe QLs and PA requirements
    90‑day mail notationLegend may note 90‑day mail availability depending on product
    inv-244: EMGALITY prefilled syringes QL (100 mg)
    EMGALITY prefilled syringes (100 mg) QL9 syringes per 180 days
    EMGALITY auto‑injector QL1 syringe per 28 days for auto‑injector presentation
    PA appliesEMGALITY entries include PA in addition to QLs
    inv-245: rizatriptan QL
    Rizatriptan QL18 tablets per 30 days (oral and ODT formulations)
    Sumatriptan nasal spray QL12 units per 30 days
    DHE injection QLDihydroergotamine (D.H.E. 45) = 10 ampules per 30 days
    inv-246: dihydroergotamine mesylate inj QL
    Dihydroergotamine inj QL10 ampules per 30 days
    EMGALITY multiple presentationsEMGALITY prefilled syringes = 9 syringes/180 days; auto‑injector = 1 syringe/28 days
    Migraine agent groupingEntries include PA and QL in migraine section
    inv-247: EMGALITY auto-injector QL
    EMGALITY auto‑injector QL1 syringe per 28 days
    PA and 90 notationPA and 90‑day mail‑order flags may appear in formulary legend for biologics
    Presentation‑dependent QLsAuto‑injector vs prefilled syringe presentations have different QLs
    inv-248: EMGALITY prefilled syr QL (100 mg)
    EMGALITY prefilled syringes (100 mg) QL9 syringes per 180 days
    Alternate strength entriesMultiple EMGALITY strengths/presentations listed with corresponding QLs
    PA requirementPA is indicated for EMGALITY in addition to QL
    inv-249: rizatriptan tablets QL
    Rizatriptan tablets QL18 tablets per 30 days
    OTC vs Rx formsODT and standard tablets share same QL in formulary entries
    Acute therapy limitQL aligns with episodic migraine acute treatment patterns
    inv-250: sumatriptan nasal spray QL
    Sumatriptan nasal spray QL12 units per 30 days
    Injectable/nasal parityInjectable and nasal presentations list unit‑based monthly QLs
    Claims submissionEnsure unit type (sprays/units) is used on claim to match QL
    inv-251: clobazam suspension QL
    Clobazam suspension QL480 mLs per 30 days
    Liquid antiepileptic QLsLarge mL allowances reflect chronic dosing for pediatric/adult needs
    PA/90 flagsSome formulations may include PA or 90‑day mail indicators in legend
    inv-252: gabapentin 100 mg QL
    Gabapentin 100 mg capsule QL720 capsules per 30 days
    Gabapentin oral solution QL1500 mLs per 30 days
    High volume allowancesSome neuropathic agents list very large monthly QLs for chronic therapy
    inv-253: gabapentin solution QL
    Gabapentin oral solution QL1500 mLs per 30 days
    Oral solution high volumeLarge mL QLs accommodate ongoing dosing requirements
    Claims detailSubmit claims with accurate mL quantity and days' supply to reflect QL
    inv-254: NAYZILAM QL
    NAYZILAM QL10 sprays per 30 days
    Rescue medication limitsNAYZILAM (midazolam nasal spray) limited to 10 sprays/30 days
    PA/90 notesPA may apply for some rescue delivery systems; check listing
    inv-255: pregabalin 25 mg QL
    Pregabalin 25 mg QL360 capsules per 30 days
    Strength‑based QLsHigher strengths have proportionally lower QLs in some entries
    Chronic therapy limitsHigh monthly capsule counts reflect chronic neuropathic use
    inv-256: vigabatrin (Sabril) QL
    Vigabatrin (Sabril) QL180 packets/tablets per 30 days
    PA requirementVigabatrin entries include PA in addition to the QL
    Restricted agent noteAgent is highly regulated — follow PA and QL when submitting claims
    inv-257: tizanidine 2 mg QL
    Tizanidine 2 mg QL180 tablets per 30 days
    Muscle relaxant QLsTizanidine and similar agents may have high monthly tablet QLs
    Claims accuracyEnsure strength and tablet count match QL on claim
    inv-258: potassium chloride QL and PA note
    Potassium chloride oral solution PA notePA applies to oral solution for members >=13 years
    Other KCl formsTablets/capsules have standard listings; solution form triggers PA for adolescents/adults
    Submission guidanceProviders must include age/dose documentation when PA applies
    inv-259: BERINERT QL
    BERINERT QL (factor)10 vials per 30 days
    PA and SPBERINERT is PA‑required and SP‑designated
    Exceedance riskRequests beyond 10 vials/30 days may be denied without PA
    inv-260: HAEGARDA QL
    HAEGARDA QL27 vials/28 days and 18 vials/28 days depending on unit strength
    PA and SPHAEGARDA entries include PA and SP designations
    Claims implicationVial limits enforced per 28‑day period as listed
    inv-261: enoxaparin prefilled syringes QL
    Enoxaparin prefilled syringes QL30 syringes per 365 days
    Annual syringe limitQL expressed over 365 days for enoxaparin prefilled syringes
    Use caseReflects prophylactic/long‑term anticoagulation presentation handling
    inv-262: eltrombopag (Promacta) QLs
    Eltrombopag (Promacta) QLs30 packets/30 days; 30 tablets/30 days; 60 tablets/30 days depending on strength
    SP designationPromacta entries include SP in some presentations
    Strength‑dependent limitsCheck specific strength for exact monthly packet/tablet QL
    inv-263: apixaban (Eliquis) QL examples
    Apixaban (Eliquis) QL examplesExamples include QL 74 capsules/30 days or 60 tablets/30 days depending on presentation
    Starter packs and boxesStarter packs and suspension box limits listed separately
    Claims noteEnsure presentation (tablet vs suspension) matches QL on claim

    Specialty Distribution and Administration Sites

    Note

    Accredo preferred for specialty dispensing

    Accredo is the preferred in‑network specialty pharmacy for BCBSNM specialty drugs; limited distribution pharmacies are used when Accredo cannot supply the product.

    Note

    SP products may require specialty site of care

    Some SP‑flagged products (e.g., CAYSTON) may require specialty pharmacy dispensing or have site‑of‑care implications such as infusion center or home administration.

    Note

    SP designation implies specialty handling

    Specialty designation (SP) indicates specialty handling, potential site‑of‑care controls, and may require specialty pharmacy documentation and routing.

    Note

    LA injectables imply clinical administration and PA

    Long‑acting injectable (LAI) agents listed with syringe/kit QLs and PA imply administration in a clinical setting (infusion center or office); providers should plan for prior authorization and appropriate site‑of‑care billing.

    Note

    MS agents: infusion/office/SP handling

    Some multiple sclerosis agents and other SP‑designated drugs may be managed through infusion center, office administration, or specialty pharmacy channels and require QL and SP compliance.

    Note

    Specialty pharmacy management for SP items

    Products designated 'SP' are managed through specialty pharmacy programs and require specialty documentation, routing, and adherence to QL and PA controls.

    Note

    SP designation common for injectable/coagulation products

    Many injectable and coagulation products are designated 'SP' and will follow specialty pharmacy distribution and documentation practices.

    Biosimilar Notes and Examples

    Billing Rule

    Adalimumab QL and SP handling

    Adalimumab biosimilars and reference products carry QL and SP flags (e.g., QL 2 syringes/28 days) — ensure claims reflect the listed quantity limits and specialty handling.

    Billing Rule

    Adalimumab: QL (2 syringes/28 days), SP

    Adalimumab entries show QL (2 syringes/28 days) and SP designation; providers must adhere to these limits and specialty routing when prescribing or billing.

    Billing Rule

    Biosimilar adalimumab: QL and SP noted

    Adalimumab biosimilar entries repeat QL and SP requirements (e.g., 2 syringes/28 days) — claims and dispensing must conform to these controls.

    Background and Scope

    Background: Specialty drugs are prescription medications used to treat complex, chronic conditions that often require special handling (for example, refrigeration), specialized administration (injection or infusion), and care coordination. The formulary applies per‑product utilization management such as Prior Authorization (PA), Quantity Limits (QL), Step Therapy (ST), and Specialty (SP) routing. For opioid safety the plan uses a morphine‑equivalent threshold (ME90) and an initial immediate‑release opioid supply limit for opioid‑naive members of 7 days. Specialty drugs frequently must be dispensed by a participating specialty supplier (Accredo preferred) and the formulary implements a Specialty Pharmacy Split Fill Program to manage initial specialty dispensing.

    Definitions and Formulary Abbreviations

    Key Contacts and How to Request Authorization

    Documentation Required

    PA submission channels (fax/phone/online)

    Submit PA requests by fax, phone, or online (Fax 1‑877‑243‑6930; Phone 1‑800‑285‑9426 TTY/TDD 711; MyPrime.com or CoverMyMeds.com) — use these channels to provide required documentation for PA determinations.

    Note

    Member Services contact for providers and members

    For additional assistance with coverage, exceptions, or formulary interpretation contact BCBSNM Member Services at 1‑866‑689‑1523 (TTY/TDD 711) during business hours.

    Policy Revision History

    January 2026document updateLatest

    Formulary drug list and utilization controls updated and published (drug list date on front cover).